Article Details
Retrieved on: 2020-12-02 18:00:00
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
In phase III trials testing various PI- and immunomodulatory agent-based regimens, adding the anti-CD38 <b>monoclonal antibody</b> daratumumab resulted in ...
Article found on: www.medpagetoday.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here